DCTH Delcath Systems Inc Sotuvning operatsion marjasi

Ommaviy kompaniya Delcath Systems, Inc. (DCTH) logotipi

Melanoma davolash uchun mo‘ljallangan Hepzato tizimi savdolari o‘sishi Delcath Systems, Inc. (DCTH) kompaniyasining daromadlarini tezlashtirmoqda va operatsion foyda marjasida faol impuls yaratmoqda, u hozirda taxminan 5.20 ni tashkil etadi. Biznes modeli yuqori marjali sarflanadigan materiallar orqali jigar metastazlarining maqsadli terapiyasi nishasini egallashga asoslangan. Strukturaviy moslashuvchanlik ishlab chiqarish va klinik sinovlarni to‘liq tashqi hamkorlarga autsorsing qilish orqali ta’minlanmoqda.

DCTH: Delcath Systems Inc Operatsion foyda normasi 04.07.2022 - 19.11.2026

DCTH (Delcath Systems): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Kompaniyaning fundamental tahlili:DCTH, Delcath Corp
delcath.com asosiy tovari

Ushbu ko'rsatkich operatsion foydaning umumiy daromadga nisbati sifatida hisoblanadi. Mazkur ko'rsatkich moliyaviy lift va soliq majburiyatlarini hisobga olgunga qadar xarajatlarni boshqarish samaradorligini belgilaydi. Delcath Systems, Inc. (DCTH) uchun bu onkologiya jamoasining tibbiy qurilmalardagi innovatsiyalarni monetizatsiya qilish qobiliyatini aks ettiradi. Klinik sinovlarning samaradorligi operatsion natijaga bevosita ta'sir ko'rsatadi. Operatsion foyda marjasini tahlil qilish orqali investor asosiy biznesning haqiqiy daromadliligini baholaydi.

Raqobatchilar tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|Y-mAbs Therapeutics - Operatsion foyda normasi|AURA (Aura Biosciences Inc) - Operatsion marja|Sotuvning operatsion rentabelligi candeltx.com CADL|Operatsion marja ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operatsion foyda normasi|Operatsion rentabellik Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operatsion rentabellik|TuHURA Biosciences Inc. - Operatsion marja|TARA - Operatsion marja|FATE (Fate Therapeutics) - Sotuvning operatsion marjasi|Sotuvning operatsion marjasi Aadi Bioscience, Inc.|Sotuvning operatsion marjasi TCRX|Operatsion rentabellik CSBR|Operatsion marja XBIT|Operatsion faoliyat rentabelligi CEL-SCI Corp.|Operatsion rentabellik ostherapies.com OSTX|RADX: Operatsion foyda bo'yicha sotuv rentabelligi|ARTV: Sotuvning operatsion marjasi|ANL (Adlai Nortye) - Operatsion foyda bo'yicha sotuv rentabelligi|Veru (VERU) - Operatsion rentabellik|Sotuvning operatsion marjasi Tempest Therapeutics Inc|Operatsion rentabellik Xilio Therapeutics|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja